Log in to search using one of your social media accounts:

 

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML
Conclusion A single-institutional retrospective analysis found no significant differences in outcomes using GCLAC or CLAG for rrAML patients, though formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was higher than CLAG which should be considered when evaluating salvage chemotherapy options. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 23, 2017 Category: Cancer & Oncology Source Type: research

Results of upfront therapy for marginal zone lymphoma
Publication date: Available online 23 September 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): José L. Ortega, Fernando Cabanillas, Noridza Rivera, Maribel Tirado-Gomez, Deana Hallman, Wandaly I. Pardo, Margarita Bruno (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 23, 2017 Category: Cancer & Oncology Source Type: research

The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma
Conclusion The use of RT in NLPHL is less likely among those with advanced-stage and B-symptoms. However, we found RT to be associated with prolonged OS in all stages of NLPHL, including those with B-symptoms. Teaser We assessed the role of radiotherapy (RT) in nodular lymphocytic Hodgkin lymphoma (NLPHL), particularly among patients with advanced stage disease, and B symptoms. We found that among NLPHL patients, RT had a potential role in advanced-stage disease and those with B symptoms, suggesting further exploratory studies. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 23, 2017 Category: Cancer & Oncology Source Type: research

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Na ïve Patients
Conclusion PCPI is a practical method that predicts overall survival in newly diagnosed myeloma and facilitates broader use of MM cell proliferation for risk stratification. Teaser The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized due to technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

Consolidative radiotherapy following autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma.
Conclusions The use of consolidative radiotherapy following high-dose chemotherapy and autologous stem cell transplantation for the treatment of relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ≥2 cm following transplant there was also an improved 2-year PFS and OS. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative radiotherapy in the transplant setting. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

Treatment Patterns and Outcomes in Early Stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis
Conclusions In older patients (≥60 years) with stage I/II HL, combination of chemotherapy and consolidative radiation resulted in improved OS as compared to monotherapy. However, utilization of combination therapy in this age group seems suboptimal. It could be partly secondary to comorbidities limiting the use of CT+RT in elderly. Teaser Early stage Hodgkin lymphoma is a highly curable malignancy. However, outcomes for elderly patients remain suboptimal. We conducted a retrospective study using the National Cancer Database to assess therapies used among elderly patients with early stage Hodgkin lymphoma from 2004-2012....
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Conclusions Patients with AML have an elevated risk of CVA compared to all inpatients and mortality in this population is high. Better characterization of risk factors of stroke in this vulnerable population is still needed. Teaser Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke i...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in Relapsed or Refractory Acute Myeloid Leukemia
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2017 Category: Cancer & Oncology Source Type: research

Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
Conclusion Existence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors at the physician’s discretion. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2017 Category: Cancer & Oncology Source Type: research

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective switch from Second Generation Tyrosine Kinase Inhibitor to Imatinib.
In conclusion, this retrospective analysis shows that IM can be safely and effectively administered following optimal response to 2G-TKIs. A prospective trial exploring this approach is currently enrolling and will be needed to confirm the safety and efficacy of this therapeutic approach. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2017 Category: Cancer & Oncology Source Type: research

A Phase II, Open-Label Study of Bortezomib (Velcade ®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas
Conclusion In summary, we report that VCR is effective in MCL and iNHL. Although hematological toxicity can be an issue, this study demonstrates a high response rate to a novel combination, and provides an alternative option in transplant ineligible R/R MCL and iNHL. Teaser Bortezomib, Cladribine and Rituximab (VCR) is a novel and effective combination in mantle cell and indolent non-Hodgkin’s lymphomas. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2017 Category: Cancer & Oncology Source Type: research

Stability of spinal bone lesions in patients with Multiple Myeloma after radiotherapy - a retrospective analysis of 130 cases
Conclusions This is the first report to analyze bone density and stability in patients with multiple myeloma after irradiation using a validated scoring system on the basis of CT imaging. Palliative radiotherapy is an effective treatment with a significant increase in bone density for local response and stability without severe radiotherapy-related toxicity. Furthermore, re-calcification can be already detected at 3 months after treatment. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2017 Category: Cancer & Oncology Source Type: research

Blood Transfusion Management and Transfusion-related Outcomes in Daratumumab-treated Patients With Relapsed or Refractory Multiple Myeloma
Conclusion In SIRIUS, no RBC transfusion reactions, including hemolysis, were observed. Observations from Mount Sinai and Levine Cancer Institute, confirm that transfusions may be administered safely to daratumumab-treated patients. Graphical abstract Teaser Daratumumab binds CD38 on red blood cells (RBCs), resulting in panagglutination in blood compatibility tests. RBC transfusions and transfusion-related adverse events from the phase 2 SIRIUS clinical trial were analyzed and an in-depth analysis from 2 clinical study sites is reported. RBC transfusion-related adverse events, including hemolysis, were not observed among d...
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2017 Category: Cancer & Oncology Source Type: research

When to Consider an Allograft in Chronic Myeloid Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Eduardo Olavarria (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

BCR-ABL Negative CML-Like Disorder
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Nick Cross (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Novel Therapeutic Options in CML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Michael Deininger (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Treatment Free Remission for Chronic Myeloid Leukemia in 2017
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Timothy P. Hughes (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

MPN: Next Questions: Potential New Targets for MPN beside JAK2
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Ann Mullally (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Case Study: Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Karen Ballen (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Therapy of Myelofibrosis: Where We Are and What Next
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Srdan Verstovsek (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Understanding New WHO Classification of MPNs
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Francesco Passamonti, Barbara Mora, Margherita Maffioli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

State of the Art Update: Molecular Genetics of MPN
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Ann Mullally (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Emerging Therapies and Clinical Challenges in Chronic Myelomonocytic Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Eric Padron (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Should Molecular Genetics Guide the Decision for Allogeneic Transplant? - Con
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Guillermo F. Sanz (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Myelodysplastic Syndromes Debate: Should Molecular Genetics Guide the Decision for Allogeneic Transplant - Pro
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Corey Cutler (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

The NLRP3 Inflammasome as a Driver of the MDS Phenotype
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Alan List (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Clonal Hematopoiesis and MDS Risk
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Koichi Takahashi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

CAR T-Cell Therapies: Overcoming the Challenges and New Strategies
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Partow Kebriaei (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

T-cell ALL: New Insights to the Biology
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Jan Cools (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Use of MRD for Selection of Post Remission Therapy in Adult All Management
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Josep-Maria Ribera (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Monoclonal Antibodies in Acute Lymphocytic Leukemia
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elias Jabbour, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Progress in the Study of Pediatric ALL
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Ching-Hon Pui, St. Jude (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

New Discoveries in Biology and Molecular Markers
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Charles G. Mullighan (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Adult Acute Lymphocytic Leukemia (ALL) in 2017
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elias Jabbour, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Breast Implant-Associated Anaplastic Large Cell Lymphoma: An Update
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Roberto N. Miranda (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Advances in the Pathology of High Grade B Cell Lymphomas
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Shaoying Li, Pei Lin, Carlos Bueso-Ramos, L. Jeffrey Medeiros (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

The Impact of the Microbiome on Infectious Outcomes in Patients with Hematologic Malignancy
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Samuel A. Shelburne (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

The Impact of the Microbiome on Outcomes of Stem Cell Transplant
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Robert Jenq (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Immune Checkpoint Based Approaches in AML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Naval Daver, Guillermo Garcia-Manero, Pam Sharma, James Allison, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Co-Stimulatory Regulation of CAR T Cell Function
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Justin C. Boucher, Marco L. Davila (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Single Cell Analysis for Drug Discovery and Development
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): James R. Heath (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Next Generation Chimeric Antigen Receptor (CAR) T Cells
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Renier Brentjens (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Other Cancers in CLL, a Common Problem
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Lorenzo Falchi, Alessandra Ferrajoli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Is MRD Useful in CLL
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Paolo Ghia (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Management of Lower Risk Non-del(5q) MDS
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Valeria Santini (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

What Can Your Radiation Oncologist Do Today: Technology at Your Service to Maximize the Therapeutic Ratio
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Bouthaina Dabaja (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Myelofibrosis with Cytopenias
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Prithviraj Bose (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Polycythemia Vera: When to Move from Hydroxyurea to Second Line Therapy
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Brady L. Stein (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Management of Post ET/PV MF: Different from Primary MF
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Francesco Passamonti, Barbara Mora, Margherita Maffioli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Models in AML
Publication date: September 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement 2 Author(s): Elihu Estey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2017 Category: Cancer & Oncology Source Type: research